Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app help cancer patients fight depression?

NCT ID NCT05012124

Symptom relief Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a digital platform could improve collaborative care for depression in cancer patients. About 300 adults receiving cancer treatment with significant depression symptoms were enrolled. The platform aimed to help care managers track symptoms and coordinate treatment more effectively. The trial was terminated early, so its full impact is unknown.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital platform for collaborative care management
What this could lead to
If successful, this approach could make depression care more effective and accessible for cancer patients, improving their quality of life during treatment.
What could go wrong
The trial was terminated early, so results are limited. The digital tool may not work better than standard care, and not all patients have reliable internet access.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

297 people

The number who actually took part.

Started

Apr 2022

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients receiving active treatment (surgery, chemotherapy, immunotherapy, targeted therapy, stem cell transplant, hormone therapy, radiation therapy) for a malignancy * \>= 18 years old * Participants must be ambulatory for clinical care visits * Clinically significant depression (Patient Health Questionnaire-9 (PHQ-9) \>= 10 with at least one cardinal symptom \> 1) * Access to smartphone, tablet, or computer with internet access; or landline * Patients who do not have a smartphone will be offered assistance in obtaining a free smartphone through the government-sponsored Lifeline Phone Program for low-resourced individuals Exclusion Criteria: * Advanced cancer or other condition that limits remaining life expectancy to less than 9 months * Already engaged in or needing immediate specialty mental health care e.g., for bipolar disorder or schizophrenia * Inability to speak and read English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Depression depressive disorder hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression Hematopoietic and lymphoid cell neoplasm Malignant solid neoplasm

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • MultiCare Regional Cancer Center - Auburn

    Auburn, Washington, 98002, United States

  • MultiCare Regional Cancer Center - Gig Harbor

    Gig Harbor, Washington, 98335, United States

  • MultiCare Regional Cancer Center - Tacoma

    Tacoma, Washington, 98405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.